vs

Side-by-side financial comparison of AbCellera Biologics Inc. (ABCL) and Bank of Marin Bancorp (BMRC). Click either name above to swap in a different company.

AbCellera Biologics Inc. is the larger business by last-quarter revenue ($44.9M vs $34.1M, roughly 1.3× Bank of Marin Bancorp). Bank of Marin Bancorp runs the higher net margin — 24.9% vs -19.9%, a 44.9% gap on every dollar of revenue. Over the past eight quarters, AbCellera Biologics Inc.'s revenue compounded faster (112.3% CAGR vs 23.3%).

AbCellera Biologics Inc. is a Vancouver, British Columbia-based biotechnology company that discovers and develops antibody therapeutics. The company is best known for its leading role in the Pandemic Prevention Platform, a project of DARPA's Biological Technologies Office. AbCellera utilizes a proprietary technology platform, which they claim can develop "medical countermeasures within 60 days." Its platform for single-cell screening was initially developed at the University of British Columbia.

American River Bank was a community bank founded in 1983 by Robert H. Daneke, who served as first president and CEO, and Bill L. Withrow, the first Chairman of the Board, and served the Greater Sacramento area in California. As of 2019, It operated ten branches in Northern CA. American River Bank which offered both business and personal financial services and was a wholly owned subsidiary of American River Bankshares.

ABCL vs BMRC — Head-to-Head

Bigger by revenue
ABCL
ABCL
1.3× larger
ABCL
$44.9M
$34.1M
BMRC
Higher net margin
BMRC
BMRC
44.9% more per $
BMRC
24.9%
-19.9%
ABCL
Faster 2-yr revenue CAGR
ABCL
ABCL
Annualised
ABCL
112.3%
23.3%
BMRC

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
ABCL
ABCL
BMRC
BMRC
Revenue
$44.9M
$34.1M
Net Profit
$-8.9M
$8.5M
Gross Margin
Operating Margin
-63.7%
Net Margin
-19.9%
24.9%
Revenue YoY
788.4%
Net Profit YoY
73.9%
74.5%
EPS (diluted)
$-0.03
$0.53

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ABCL
ABCL
BMRC
BMRC
Q1 26
$34.1M
Q4 25
$44.9M
$27.0M
Q3 25
$9.0M
$30.9M
Q2 25
$17.1M
$10.3M
Q1 25
$4.2M
$27.8M
Q4 24
$5.0M
$22.2M
Q3 24
$6.5M
$27.2M
Q2 24
$7.3M
$22.5M
Net Profit
ABCL
ABCL
BMRC
BMRC
Q1 26
$8.5M
Q4 25
$-8.9M
$-39.5M
Q3 25
$-57.1M
$7.5M
Q2 25
$-34.7M
$-8.5M
Q1 25
$-45.6M
$4.9M
Q4 24
$6.0M
Q3 24
$-51.1M
$4.6M
Q2 24
$-36.9M
$-21.9M
Operating Margin
ABCL
ABCL
BMRC
BMRC
Q1 26
Q4 25
-63.7%
-212.6%
Q3 25
-851.8%
31.1%
Q2 25
-290.2%
-108.8%
Q1 25
-1479.6%
23.3%
Q4 24
43.5%
Q3 24
-1439.4%
25.7%
Q2 24
-1276.2%
-153.0%
Net Margin
ABCL
ABCL
BMRC
BMRC
Q1 26
24.9%
Q4 25
-19.9%
-146.5%
Q3 25
-637.8%
24.3%
Q2 25
-203.3%
-82.9%
Q1 25
-1077.2%
17.5%
Q4 24
27.1%
Q3 24
-785.4%
16.8%
Q2 24
-504.3%
-97.5%
EPS (diluted)
ABCL
ABCL
BMRC
BMRC
Q1 26
$0.53
Q4 25
$-0.03
$-2.48
Q3 25
$-0.19
$0.47
Q2 25
$-0.12
$-0.53
Q1 25
$-0.15
$0.30
Q4 24
$0.38
Q3 24
$-0.17
$0.28
Q2 24
$-0.13
$-1.36

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ABCL
ABCL
BMRC
BMRC
Cash + ST InvestmentsLiquidity on hand
$128.5M
Total DebtLower is stronger
Stockholders' EquityBook value
$966.9M
$394.5M
Total Assets
$1.4B
$3.9B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ABCL
ABCL
BMRC
BMRC
Q1 26
Q4 25
$128.5M
Q3 25
$83.2M
Q2 25
$92.4M
Q1 25
$159.3M
Q4 24
$156.3M
Q3 24
$126.6M
Q2 24
$148.3M
Stockholders' Equity
ABCL
ABCL
BMRC
BMRC
Q1 26
$394.5M
Q4 25
$966.9M
$394.7M
Q3 25
$964.0M
$443.8M
Q2 25
$1.0B
$438.5M
Q1 25
$1.0B
$439.6M
Q4 24
$1.1B
$435.4M
Q3 24
$1.1B
$437.0M
Q2 24
$1.1B
$434.9M
Total Assets
ABCL
ABCL
BMRC
BMRC
Q1 26
$3.9B
Q4 25
$1.4B
$3.9B
Q3 25
$1.4B
$3.9B
Q2 25
$1.4B
$3.7B
Q1 25
$1.3B
$3.8B
Q4 24
$1.4B
$3.7B
Q3 24
$1.4B
$3.8B
Q2 24
$1.4B
$3.7B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ABCL
ABCL
BMRC
BMRC
Operating Cash FlowLast quarter
$-34.7M
Free Cash FlowOCF − Capex
$-44.6M
FCF MarginFCF / Revenue
-99.4%
Capex IntensityCapex / Revenue
21.9%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-174.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ABCL
ABCL
BMRC
BMRC
Q1 26
Q4 25
$-34.7M
$39.1M
Q3 25
$-52.6M
$12.5M
Q2 25
$-32.4M
$8.0M
Q1 25
$-11.6M
$4.9M
Q4 24
$-108.6M
$28.4M
Q3 24
$-28.9M
$9.9M
Q2 24
$-30.0M
$3.4M
Free Cash Flow
ABCL
ABCL
BMRC
BMRC
Q1 26
Q4 25
$-44.6M
$37.3M
Q3 25
$-61.5M
$12.1M
Q2 25
$-45.8M
$7.1M
Q1 25
$-22.2M
$4.6M
Q4 24
$-187.0M
$27.8M
Q3 24
$-47.4M
$9.8M
Q2 24
$-50.1M
$3.4M
FCF Margin
ABCL
ABCL
BMRC
BMRC
Q1 26
Q4 25
-99.4%
138.1%
Q3 25
-687.0%
39.0%
Q2 25
-267.9%
68.7%
Q1 25
-524.0%
16.6%
Q4 24
-3702.8%
125.7%
Q3 24
-728.4%
36.0%
Q2 24
-683.8%
15.0%
Capex Intensity
ABCL
ABCL
BMRC
BMRC
Q1 26
Q4 25
21.9%
6.7%
Q3 25
99.7%
1.3%
Q2 25
78.2%
9.4%
Q1 25
251.1%
1.1%
Q4 24
1552.7%
2.3%
Q3 24
284.6%
0.4%
Q2 24
274.6%
0.4%
Cash Conversion
ABCL
ABCL
BMRC
BMRC
Q1 26
Q4 25
Q3 25
1.66×
Q2 25
Q1 25
1.01×
Q4 24
4.73×
Q3 24
2.16×
Q2 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ABCL
ABCL

Segment breakdown not available.

BMRC
BMRC

Net Interest Income$30.3M89%
Noninterest Income$3.8M11%

Related Comparisons